|
NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Aug. 19, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.
Marcus Ericsson Sets Scene for Freedom 250 race
Ashley Mastronardi delivers the pre-market update on August 19th
- Defense tech firm Lyntris (NYSE: LYNX) will make its trading debut on the NYSE.
- The firm sold 17 million shares at $17.50 apiece in its IPO.
- Lyntris will begin trading under the ticker symbol LYNX.
- INDYCAR driver Marcus Ericsson to discuss the Freedom 250 Grand Prix.
- Ericsson is coming off a victory at Markham last week.
- The Freedom 250 Grand Prix takes place August 22-23.
- LATAM Airlines (NYSE: LTM) CFO Ricardo Bottas to join NYSE Live.
- Bottas will join to discuss the firm’s Q2 earnings earlier this month.
- The airline reported a year-over-year revenue increase of 28%.
- Investors await today’s Fed Minutes and react to the latest corporate earnings.
- Approximately two-thirds of traders expect interest rates to hold steady.
- Target (NYSE: TGT), TJX (NYSE: TJX) and Lowe’s (NYSE: LOW) reported earnings this morning.
Opening Bell
Russell Investments celebrates the launch of two new ETFs, CRIB and BD
Closing Bell
Citrotech (NYSE American: CITR) celebrates its uplisting to NYSE American
For market insights, IPO activity, and today’s opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial
ข่าวที่เกี่ยวข้อง
- Genesis Momentum Powers Cellebrite’s Autumn Release: More Evidence, Deeper Insight, Broader Access for Investigations
- Genesis สร้างแรงขับเคลื่อนให้ผลิตภัณฑ์รุ่น Autumn Release ของ Cellebrite มุ่งค้นพบหลักฐานมากขึ้น เจาะลึกข้อมูลเชิงลึก และขยายการเข้าถึงข้อมูลเพื่อการสืบสวน
- Elisa taps NVIDIA and Nokia for its journey towards commercial AI-RAN in Finland
- Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer